Goldstein L S, Kavuru M S, Curtis-McCarthy P, Christie H A, Farver C, Stoller J K
Department of Pulmonary and Critical Care Medicine, Cleveland Clinic Foundation, OH, USA.
Chest. 1998 Nov;114(5):1357-62. doi: 10.1378/chest.114.5.1357.
Pulmonary alveolar proteinosis (PAP) is a rare disease of unknown etiology and variable natural history. To date, the largest series from a single institution has consisted of 68 individuals. To extend the understanding of the clinical features and natural history of PAP, we present a series of 24 patients with PAP from a single institution.
Patients with PAP were identified by a review of The Cleveland Clinic Foundation discharge database from 1965 to 1995. After identification, a chart review of the 24 selected patients was conducted. Charts were abstracted for historical, diagnostic, and therapeutic features. Diagnosis was confirmed by a review of the lung biopsy, where it was available, by a lung pathologist. Follow-up by telephone was performed with 19 patients.
Most patients (70%) were male, and smoking was common (75%; mean pack-years, 29) in the group. The mean age at initial evaluation was 43 years. Presenting symptoms were as follows: 19 patients (79%) reported dyspnea, 19 patients (79%) reported a cough, 4 patients (17%) reported hemoptysis, and 3 patients (13%) reported chest pain. The earliest available spirometry after presentation of symptoms showed a prediction of mean FEV1 of 74% (range, 45 to 99%) and a prediction of mean FVC of 76% (range, 41 to 99%). The diagnosis of PAP was established by transbronchial biopsy alone in 7 patients (29%) and by open-lung biopsy alone in 17 patients (71%). Whole lung lavage was deemed necessary in 13 patients (54%); 3 patients underwent lavage of one lung only, and 10 patients underwent bilateral whole lung lavage. Whole lung lavage was required only once in 46% of patients, and from two to four times in the remainder of patients. During the follow-up period (mean length of follow-up, 8.5 years; range, 5 months to 21 years), 25% of the patients died, but none as a result of sequelae of PAP. Half of the survivors reported persistent symptoms.
In this series, which represents one of the largest single institutional experiences with PAP reported, the clinical features are largely consistent with previously reported cases. However, contrary to early reported experiences in which open-lung biopsy was frequently required to establish PAP and in which whole lung lavage was needed, transbronchial biopsy established the diagnosis in 29% of patients and whole lung lavage could be deferred in 46% of patients.
肺泡蛋白沉积症(PAP)是一种病因不明、自然病史各异的罕见疾病。迄今为止,来自单一机构的最大病例系列包含68例患者。为了加深对PAP临床特征和自然病史的了解,我们展示了来自单一机构的24例PAP患者的病例系列。
通过回顾1965年至1995年克利夫兰诊所基金会的出院数据库来识别PAP患者。识别后,对24例选定患者的病历进行了回顾。提取病历中的病史、诊断和治疗特征。由肺病理学家对有肺活检结果的病例进行复查以确诊。对19例患者进行了电话随访。
大多数患者(70%)为男性,该组中吸烟很常见(75%;平均吸烟包年数为29)。初次评估时的平均年龄为43岁。出现的症状如下:19例患者(79%)报告有呼吸困难,19例患者(79%)报告有咳嗽,4例患者(17%)报告有咯血,3例患者(13%)报告有胸痛。症状出现后最早可获得的肺功能测定结果显示,平均FEV1预测值为74%(范围为45%至99%),平均FVC预测值为76%(范围为41%至99%)。7例患者(29%)仅通过经支气管活检确诊为PAP,17例患者(71%)仅通过开胸肺活检确诊。13例患者(54%)被认为需要进行全肺灌洗;3例患者仅对一侧肺进行了灌洗,10例患者进行了双侧全肺灌洗。46%的患者仅需进行一次全肺灌洗,其余患者需进行两至四次全肺灌洗。在随访期间(平均随访时间为8.5年;范围为5个月至21年),25%的患者死亡,但无一例死于PAP的后遗症。一半的幸存者报告有持续症状。
在这个代表已报道的最大规模单一机构PAP病例经验之一的病例系列中,临床特征在很大程度上与先前报道的病例一致。然而,与早期报道的经验不同,早期报道中经常需要开胸肺活检来确诊PAP且需要进行全肺灌洗,但本病例系列中29%的患者通过经支气管活检确诊,46%的患者可以推迟进行全肺灌洗。